ReviewCurrent opinion in hematology2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
Review in Current opinion in hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Pooled it
- Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.Clinical pharmacokinetics · 2020Trial
- Article
- Targeted Therapy Development in Acute Myeloid Leukemia.Biomedicines · 2023Review
- CD105 (Endoglin) as negative prognostic factor in AML.Scientific reports · 2019Article
- IncreasedOncoTargets and therapy · 2019Article
- RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.Oncotarget · 2017Article
- Frontline treatment of acute myeloid leukemia in adults.Critical reviews in oncology/hematology · 2017Review
- Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.Oncology letters · 2015Article
- Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Clinical lymphoma, myeloma & leukemia · 2013Article
- Article
- Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Oncotarget · 2012Article
- Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.Cytometry. Part B, Clinical cytometry · 2012Article
- Treatment of elderly acute myeloid leukemia patients.Current treatment options in oncology · 2011Article
- Article
- Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.American journal of clinical pathology · 2011Article
- Article
- Article
- Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?The Korean journal of hematology · 2010Article
- Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.The Journal of molecular diagnostics : JMD · 2010Review
Corrections and comments
- Commented on byMyeloid disease.2009
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn recent years, new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukemia (AML). However, prognostic markers cannot guide the decision for a specific treatment, as they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus, predictive markers can guide clinical decision-making. RECENT
findingsIn young adults, mutations of the nucleophosmin (gene 9NPM1) in the absence of concurrent FLT3-internal tandem duplication (ITD) (FLT3-ITD) have impressive prognostic and, beyond prognostication, predictive properties. This NPM1/FLT3-ITD genotype predicts equivalent favorable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed on older adults, the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. SUMMARY: The discovery of new prognostic and predictive markers has increased our understanding of leukemogenesis and this may lead to improved prognostication and, more important, to novel genotype-specific treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.